UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

PloS one, 2015-06, Vol.10 (6), p.e0130142-e0130142

2015

Volltextzugriff (PDF)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

Journal of experimental & clinical cancer research, 2010-05, Vol.29 (1), p.58-58, Article 58

2010

Volltextzugriff (PDF)

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials

Lung cancer (Amsterdam, Netherlands), 2009-01, Vol.63 (1), p.50-57

2009

Volltextzugriff (PDF)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Journal of experimental & clinical cancer research, 2011-05, Vol.30 (1), p.54-54, Article 54

2011

Volltextzugriff (PDF)

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials

BMC cancer, 2010-12, Vol.10 (1), p.675-675, Article 675

2010

Volltextzugriff (PDF)

Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?

Chest, 2006-12, Vol.130 (6), p.1808-1816

2006

Volltextzugriff (PDF)

Targeting targeted agents: open issues for clinical trial design

Journal of experimental & clinical cancer research, 2009-05, Vol.28 (1), p.66-66, Article 66

2009

Volltextzugriff (PDF)

Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?

Clinical breast cancer, 2007-04, Vol.7 (7), p.550-554

2007

Volltextzugriff (PDF)

Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?

Cancer, 2009-08, Vol.115 (15), p.3446-3456

2009

Volltextzugriff (PDF)

Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?

Cancer, 2007-08, Vol.110 (3), p.525-533

2007

Volltextzugriff (PDF)

Benefit of taxanes as adjuvant chemotherapy for early breast cancer : Pooled analysis of 15,500 patients

Cancer, 2006-06, Vol.106 (11), p.2337-2344

2006

Volltextzugriff (PDF)

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

Breast cancer research and treatment, 2008-05, Vol.109 (2), p.231-239

2008

Volltextzugriff (PDF)

Does Hormone Treatment Added to Radiotherapy Improve Outcome in Locally Advanced Prostate Cancer?: Meta-Analysis of Randomized Trials

Cancer, 2009-08, Vol.115 (15), p.3446-3456

2009

Volltextzugriff (PDF)

Do Adjuvant Aromatase Inhibitors Increase the Cardiovascular Risk in Postmenopausal Women With Early Breast Cancer? : Meta-Analysis of Randomized Trials

Cancer, 2008-01, Vol.112 (2), p.260-267

2008

Volltextzugriff (PDF)

Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? : A meta-analysis of 20 phase 3 trials

Cancer, 2007-08, Vol.110 (3), p.525-533

2007

Volltextzugriff (PDF)

Clinical Impact of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in First-Line Treatment of Metastatic Colorectal Cancer: Meta-Analytical Estimation and Implications for Therapeutic Strategies

Cancer, 2012-03, Vol.118 (6), p.1523-1532

2012

Volltextzugriff (PDF)

Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer

Cancer, 2012-03, Vol.118 (6), p.1523-1532

2012

Volltextzugriff (PDF)

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

Expert opinion on therapeutic targets, 2011-10, Vol.15 (10), p.1183-1196

2011

Volltextzugriff (PDF)

Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research

Expert opinion on biological therapy, 2017-04, Vol.17 (4), p.497-506

2017

Volltextzugriff (PDF)

Cetuximab for metastatic colorectal cancer

The New England journal of medicine, 2009-07, Vol.361 (1), p.95

2009

Volltextzugriff (PDF)

Taxanes as Primary Chemotherapy for Early Breast Cancer : Meta-analysis of Randomized Trials

Cancer, 2008-07, Vol.113 (2), p.238-246

2008

Volltextzugriff (PDF)

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

Journal of thoracic oncology, 2012-04, Vol.7 (4), p.672-680

2012

Volltextzugriff (PDF)

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer

Translational lung cancer research, 2015-12, Vol.4 (6), p.704-712

2015

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(47)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(37)
Humans
(36)
Oncology
(31)
Female
(20)
Breast Neoplasms - Drug Therapy
(19)
Randomized Controlled Trials As Topic
(14)
Treatment Outcome
(14)
Tumors
(14)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Meta-Analysis
(11)
Middle Aged
(11)
Breast Cancer
(10)
Chemotherapy
(10)
Disease-Free Survival
(10)
Survival Analysis
(10)
Aged
(9)
Breast Neoplasms - Pathology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials

Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?

Targeting targeted agents: open issues for clinical trial design

Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?

Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?

Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund

Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?

Benefit of taxanes as adjuvant chemotherapy for early breast cancer : Pooled analysis of 15,500 patients

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

Does Hormone Treatment Added to Radiotherapy Improve Outcome in Locally Advanced Prostate Cancer?: Meta-Analysis of Randomized Trials

Do Adjuvant Aromatase Inhibitors Increase the Cardiovascular Risk in Postmenopausal Women With Early Breast Cancer? : Meta-Analysis of Randomized Trials

Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? : A meta-analysis of 20 phase 3 trials

Clinical Impact of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in First-Line Treatment of Metastatic Colorectal Cancer: Meta-Analytical Estimation and Implications for Therapeutic Strategies

Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research

Cetuximab for metastatic colorectal cancer

Taxanes as Primary Chemotherapy for Early Breast Cancer : Meta-analysis of Randomized Trials

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer

Suchergebnisse filtern